Marked Bone Marrow Eosinophilia Post-Azacitidine + Ivosidenib Treatment for Acute Myeloid Leukemia - PubMed
8 hours ago
- #Ivosidenib
- #Bone Marrow Eosinophilia
- #Acute Myeloid Leukemia
- A case of marked bone marrow eosinophilia observed following treatment with azacitidine and ivosidenib for acute myeloid leukemia (AML).
- The study references literature on post-chemotherapy bone marrow changes in acute leukemia, including residual disease detection via immunohistochemistry.
- It notes FDA approval for ivosidenib combined with azacitidine in newly diagnosed AML with an IDH1 mutation.
- Long-term results from the AGILE study support the efficacy of azacitidine plus ivosidenib versus placebo in IDH1-mutated AML.